JP2016540024A - 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 - Google Patents

新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 Download PDF

Info

Publication number
JP2016540024A
JP2016540024A JP2016539198A JP2016539198A JP2016540024A JP 2016540024 A JP2016540024 A JP 2016540024A JP 2016539198 A JP2016539198 A JP 2016539198A JP 2016539198 A JP2016539198 A JP 2016539198A JP 2016540024 A JP2016540024 A JP 2016540024A
Authority
JP
Japan
Prior art keywords
compound
mmol
formula
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016539198A
Other languages
English (en)
Japanese (ja)
Inventor
リー，チャンシク
ヤン，ヒュン‐モ
リー，チャンコン
べ，ミション
キム，ソヨン
チョイ，ヨンギル
ハ，ニナ
リー，ジェクワン
オー，ジュンテク
ソン，ヒェシュン
キム，イルヒャン
チョイ，デキュ
ミン，ジェキ
リム，ヒョジン
ベ，デクウォン
Original Assignee
チョン クン ダン ファーマシューティカル コーポレーション
チョン クン ダン ファーマシューティカル コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チョン クン ダン ファーマシューティカル コーポレーション, チョン クン ダン ファーマシューティカル コーポレーション filed Critical チョン クン ダン ファーマシューティカル コーポレーション
Publication of JP2016540024A publication Critical patent/JP2016540024A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016539198A 2013-12-12 2014-12-12 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 Pending JP2016540024A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0154455 2013-12-12
KR20130154455 2013-12-12
PCT/IB2014/002768 WO2015087151A1 (en) 2013-12-12 2014-12-12 Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076529A Division JP6561167B2 (ja) 2013-12-12 2018-04-12 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物

Publications (1)

Publication Number Publication Date
JP2016540024A true JP2016540024A (ja) 2016-12-22

Family

ID=53370682

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016539198A Pending JP2016540024A (ja) 2013-12-12 2014-12-12 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物
JP2018076529A Expired - Fee Related JP6561167B2 (ja) 2013-12-12 2018-04-12 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018076529A Expired - Fee Related JP6561167B2 (ja) 2013-12-12 2018-04-12 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物

Country Status (12)

Country Link
US (1) US9650379B2 (https=)
EP (1) EP3080125B1 (https=)
JP (2) JP2016540024A (https=)
KR (1) KR101689394B1 (https=)
CN (1) CN105940001B (https=)
DK (1) DK3080125T3 (https=)
ES (1) ES2704704T3 (https=)
HR (1) HRP20181965T1 (https=)
PL (1) PL3080125T3 (https=)
PT (1) PT3080125T (https=)
TR (1) TR201900057T4 (https=)
WO (1) WO2015087151A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001354B (zh) * 2014-04-11 2021-06-22 台北医学大学 组蛋白去乙酰酶抑制剂
RU2695227C9 (ru) * 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
CN108026056B (zh) 2015-07-27 2021-08-03 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
JP6697074B2 (ja) 2015-10-12 2020-05-20 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2020076129A1 (en) * 2018-10-12 2020-04-16 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP2022538284A (ja) 2019-06-27 2022-09-01 ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション Ｈｄａｃ６活性化マクロファージ、その組成物および使用
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途
CN115417877B (zh) * 2022-09-20 2024-05-14 杭州师范大学 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012178208A2 (en) * 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013052110A1 (en) * 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2013078544A1 (en) * 2011-11-29 2013-06-06 Beta Pharma Canada Inc. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
KR101168801B1 (ko) 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
ES2736200T3 (es) 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012178208A2 (en) * 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
WO2013052110A1 (en) * 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2013078544A1 (en) * 2011-11-29 2013-06-06 Beta Pharma Canada Inc. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤
JP7630502B2 (ja) 2019-10-09 2025-02-17 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Also Published As

Publication number Publication date
US20160289230A1 (en) 2016-10-06
JP6561167B2 (ja) 2019-08-14
JP2018109068A (ja) 2018-07-12
EP3080125A1 (en) 2016-10-19
CN105940001B (zh) 2018-02-06
EP3080125A4 (en) 2017-08-02
PL3080125T3 (pl) 2019-06-28
KR101689394B1 (ko) 2016-12-23
WO2015087151A1 (en) 2015-06-18
US9650379B2 (en) 2017-05-16
DK3080125T3 (en) 2019-01-07
HRP20181965T1 (hr) 2019-02-08
PT3080125T (pt) 2018-12-14
TR201900057T4 (tr) 2019-01-21
ES2704704T3 (es) 2019-03-19
CN105940001A (zh) 2016-09-14
EP3080125B1 (en) 2018-10-10
KR20150068923A (ko) 2015-06-22

Similar Documents

Publication Publication Date Title
JP6561167B2 (ja) 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物
AU2017395023B2 (en) Compounds and methods for CDK8 modulation and indications therefor
EP3806853B1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
JP7035055B2 (ja) Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体および疾患の処置におけるそれらの使用
CN114867727A (zh) Tau蛋白靶向化合物及相关使用方法
CN114650868A (zh) Helios的小分子降解剂及其使用方法
JP2022527216A (ja) Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
EA024293B1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ с-kit КИНАЗЫ
TW202500565A (zh) Shp2磷酸酶抑制劑及其使用方法
EP3283475B1 (en) 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
TW202214627A (zh) Ｂｒａｆ降解劑
JP2023539663A (ja) 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
JP2019509978A (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
KR20240109977A (ko) Kif18a의 스피로 인돌린 억제제
NZ728122A (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
CA3025220A1 (en) Tricyclic heterocylic derivatives
CA3184990A1 (en) Pyridazinyl amino derivatives as alk5 inhibitors
EP3782997A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
KR20240168922A (ko) 방향족 헤테로사이클릭 화합물, 그의 제조 방법 및 그의 용도
CN107848971B (zh) 杂环化合物
CN105085436B (zh) 磺酰胺类衍生物及其在药物上的应用
JP2024509625A (ja) ベンゾイソオキサゾール誘導体及びその使用
CA2916557A1 (en) Phthalazine derivatives
HK1225018A1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180412